Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.86 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12008990 | 0.96 | KMT2A (0.86) | KMT2AFFAR1MEN1GPR55NPC1 | |
| SCHEMBL12008977 | 0.93 | KMT2A (1.00) | KMT2AFFAR1MEN1NPC1MAPT | |
| SCHEMBL12008890 | 0.93 | KMT2A (1.00) | KMT2AFFAR1MEN1NPC1MAPT | |
| SCHEMBL12008872 | 0.92 | KMT2A (0.98) | KMT2AFFAR1MEN1NPC1MAPT | |
| SCHEMBL12009002 | 0.89 | KMT2A (0.74) | KMT2AFFAR1MEN1GPR55NPC1 | |
| SCHEMBL12008972 | 0.87 | PKM (0.73) | KMT2AFFAR1MEN1GPR55NPC1 | |
| SCHEMBL13745374 | 0.85 | KMT2A (0.82) | KMT2AFFAR1MEN1GPR55NPC1 | |
| SCHEMBL12008991 | 0.85 | KMT2A (0.69) | KMT2AFFAR1MEN1GPR55NPC1 | |
| SCHEMBL12008898 | 0.85 | FFAR1 (0.68) | KMT2AFFAR1MEN1GPR55NPC1 | |
| SCHEMBL12008887 | 0.85 | KMT2A (0.84) | KMT2AFFAR1MEN1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | DASGUPTA RAMANUJ (US) | 2017-02-23 | — | — | US | disclosed |
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | DASGUPTA RAMANUJ (US) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | KMT2A 4591/4885FFAR1 2541/4885MEN1 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.